Table 3.
Characteristics of therapeutic response for 24 included studies (SR-aGVHD)*.
| Studies | Study design | N | Response/event (n) | cGVHD incidence (%) | 6-month overall survival | Median follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|
| ORR | ORR at 28 days | CRR | CRR at 28 days | ||||||
| Zeiser, 2020 | RCT | 154 | NA | 96 | NA | 53 | NA | NA | 5.04 |
| Modemann, 2020 | Retrospective | 18 | 10 | NA | 8 | NA | 66.70 | NA | NA |
| Lancman, 2018 | Case report | 4 | NA | NA | 3 | 2 | NA | 0.75 | NA |
| Assouan, 2017 | Retrospective | 10 | NA | NA | 5 | NA | NA | 0.70 | 4.47 |
| Wei, 2021 | Retrospective | 23 | 20 | NA | 13 | NA | 21.74 | NA | 14.43 |
| Leung, 2022 | Retrospective | 26 | 19 | 19 | 15 | 8 | 11.54 | NA | NA |
| Moiseev, 2020 | Prospective | 32 | 24 | NA | 20 | NA | 37.50 | NA | NA |
| Jagasia, 2020 | Prospective | 71 | 52 | 39 | 40 | 19 | 5.63 | 0.51 | 10.77 |
| Biliński, 2021 | Case report | 4 | NA | NA | 2 | NA | NA | NA | NA |
| Liu, 2021 | Retrospective | 40 | 34 | NA | 25 | NA | 7.50 | 0.57 | 8.20 |
| Laisne, 2020 | Retrospective | 29 | NA | NA | 19 | 6 | NA | NA | 16.00 |
| González, 2018 | Prospective | 13 | NA | NA | 4 | NA | NA | NA | NA |
| Maldonado, 2017 | Case report | 3 | 3 | NA | 2 | NA | NA | NA | 24.00 |
| Maldonado, 2021 | Retrospective | 9 | 7 | NA | 4 | NA | NA | NA | NA |
| Meng, 2019 | Retrospective | 12 | 10 | NA | 7 | NA | NA | NA | NA |
| Mozo, 2021 | Retrospective | 8 | 7 | NA | 3 | NA | 12.50 | NA | NA |
| Khandelwal, 2017 | Retrospective | 13 | 5 | NA | 1 | NA | NA | NA | NA |
| Zeiser, 2015 | Retrospective | 54 | 44 | NA | 25 | NA | NA | 0.79 | 6.18 |
| Abedin, 2019 | Retrospective | 19 | 17 | 16 | 12 | 9 | NA | NA | NA |
| Dang, 2020 | Retrospective | 10 | 10 | NA | NA | NA | NA | NA | 2.50 |
| Uygun, 2020 | Retrospective | 13 | 11 | NA | 9 | NA | NA | NA | NA |
| Gómez, 2019 | Retrospective | 23 | 16 | NA | 5 | NA | NA | 0.47 | NA |
| Toama, 2020 | Retrospective | 36 | 14 | NA | 6 | NA | NA | NA | NA |
| Zhao, 2020 | Prospective | 64 | NA | 56 | NA | 47 | NA | 0.68 | 15.50 |
CRR, complete response rate; NA, not available; ORR, overall response rate; RCT, randomized controlled trials; SR-aGVHD, steroid-refractory acute graft-versus-host disease; SR-cGVHD, steroid-refractory chronic graft-versus-host disease.*Thirteen studies included both SR-aGVHD and SR-cGVHD analysis.